TrialJournal of Alzheimer's disease : JAD2018

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.

Gordon K Wilcock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.